IC
CTNM

Ikarian Capital’s Contineum Therapeutics CTNM Stock Holding History

Ikarian Capital’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.6M Buy
807,874
+525,000
+186% +$7.04M 0.86% 33
2025
Q4 		$3.23M Buy
+282,874
New +$3.23M 0.25% 79

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ikarian Capital's CTNM Position: Q1 2026 in Review

Ikarian Capital increased its Contineum Therapeutics (CTNM) stake by 186% in Q1 2026, buying an estimated $7.04M and bringing the position to 807,874 shares worth $10.6M. The position accounts for 0.86% of the portfolio, ranked #33.

Ikarian Capital first reported a position in CTNM in Q4 2025 and has held it in 2 quarters since. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Ikarian Capital held 807,874 shares of Contineum Therapeutics worth $10.6M as of Q1 2026.
  • Ikarian Capital bought 525,000 Contineum Therapeutics shares in Q1 2026, an estimated $7.04M.
  • Contineum Therapeutics made up 0.86% of Ikarian Capital's portfolio in Q1 2026, its #33 holding.
  • Ikarian Capital first reported a position in Contineum Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.